PEGylation Application
Modified adenosine deaminase (ADA), the first protein medication to be sold in PEGylated form, was created by Frank Davis and associates in the 1970s. Severe combined immunodeficiency disease (SCID) is primarily treated in young adults with enzyme ADA. ADA has a fairly brief plasma half-life of a few minutes, similar to most other enzymes. In mice, the half-life of bovine ADA was extended to 24 hours by conjugating PEG to it. PEG-ADA was injected intramuscularly (IM) into two youngsters in subsequent experiments.
Long-lasting hemophilia medications are another well-known example of PEGylation technology’s success. A rare blood condition caused by a lack of clotting factor called hemophilia. Consequently, recombinant factor VIII products are used to treat it.
